Presentations

Immuno-Oncology at a Tipping Point
Cardinal Bernardin Cancer Center Retreat, Loyola University, Chicago, IL, July 29, 2016

Impersonalization of Cancer: Development of a Universal Cancer Vaccine
MITR Conference University of Washington, Seattle, WA, July 18, 2016

Impersonalization of Cancer: Development of a Universal Cancer Vaccine
Agonox Maui Meeting, Maui, HI, June 10, 2016

UbiVac, Sachs Immuno-Oncology Investor Forum, Chicago, IL, June 3, 2016

Recent Advances for the Immunotherapy of Advanced Cancer
Molecular Genetics Section, Taiwan Joint Cancer Conference, Taipei, Taiwan, May 14, 2016

Immuno-Oncology at a Tipping Point
Bayer, Berlin, Germany, May 2, 2016

A Universal Cancer Vaccine Alternative to Personalized Cancer Vaccine Strategies
Tumor Immunology Meets Oncology (TIMO), Halle, Germany, April 28, 2016

Increased IgG antibody responses to neoepitope and native peptides containing high affinity domains for MHCI
Poster presented by Tyler W. Hulett, AACR, New Orleans, LA, April 16-20, 2016

Timing Of PD-1 Blockade Is Critical To Successful Synergy With OX40 Costimulation In Preclinical Mammary Tumor Models
Oral presentation, David Messenheimer, AACR, New Orleans, LA, April 16-20, 2016

Immunotherapy at a Tipping Point
Molecular Med TriCon, San Francisco, CA, March 10-11, 2016

Cancer Vaccines and Combination Immunotherapy. At Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer
Institute of Medicine, Keck Building of The National Academies of Sciences, Engineering, and Medicine, Washington, DC 20001, February 29, 2016

The Promise of Immunotherpy in Curing Patients with Cancer
Annual meeting of the Oncology Association of Naturopathic Physicians, Phoenix, AZ, February 28, 2016

The Next Phase for Cancer Immunotherapy
Janssen Research Center, Leiden, The Netherlands, February 8, 2016.

Clinical Updates for Novel Targets and Pathways: Application of Technologies and what they tell us?
PEP Talk, San Diego January 18, 2016

Combining Targeted Therapy with a NextGen immunotherapy: Crazy Idea or Opportunity to Convert CRs into Cures?
Ignyta, San Diego, CA, December 14, 2015

Developing Cancer Immunotherapy Strategies that Change the Tumor Microenvironment and Eliminate Cancer At Melanoma Bridge Meeting, Napoli, Italy, December 3rd 2015.

Multispectral Imaging and Escape from Immune-Editing: A Story About Problem Relationships and Novel Intervention
At Society for Melanoma Research meeting, San Francisco, CA, November 17, 2015

Preliminary Analysis of Immune Responses in Patients Enrolled in a Phase II Trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for Adjuvant Treatment of Stage IIIa or IIIb NSCLC
Poster presented by Rachel Sanborn, MD, Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, Nov. 5-8, 2015

Autophagosome and Peptide Vaccines; and “Potential Vaccine: Vaccine and Vaccine-other combinations”
Immunotherapy Conference, Hoeboken, NJ, October 23, 2015

UbiVac’s Drug Development Strategy
Oregon BioScience Association Cancer Immunotherapy BioForum, Portland, OR October 20, 2015

Immune Biomarkers
2015 China Cancer Immunotherapy Workshop China Center for Food and Drug International Exchange, Capital Hotel, Beijing, China, June 23, 2015

DRibble Immunotherapy for NSCLC
Lung Cancer Research Team (LCRT), Chicago, IL, May 29, 2015

UbiVac’s Immuno-Oncology Pipeline
Sachs International Immuno-Oncology Forum, Chicago, IL, May 29, 2015

Integrating NGS, Immunoprofiling and Microbiome Analysis to Stratify Patients for Clinical Trials and Ultimately Tailor Immunotherapy for Patients with Cancer
Annual Oncology Symposium: Personalized Medicine, Swedish Medical Center, Seattle, WA, May 8, 2015

The Transformation of Oncology: A strategic review of Immunoscore and Immunotherapy
Keio University, Tokyo, Japan, April 22, 2015

Strategic Considerations for Advancing Patient Outcomes with Immuno-Oncology: Role for Vaccines Grand Rounds, St. Johns Medical Center, Santa Monica, CA, February 25, 2015

The Immunoscore and Immunoprofile: Assessing Anti-Cancer Immunity as a Biomarker to Stratify Patients and Tailor Therapy
Trial Design Focus: Biomarkers to Predict Patient Responses to Immunotherapy, NRG Oncology Semiannual Meeting, Manchester Grand Hyatt San Diego, California February 5 – 8, 2015

Transformation of Oncology
Schafer Memorial Lecture, Georgetown University Cancer Center, Washington, DC, December 5, 2014

Co-stimulatory/Inflammatory Agonists, CD137, TLR3/7/8 agonists and anti-OX40-vaccine combinations
HNSCC Clinical Trials Planning Meeting (CTPM), NCI, NIH, Bethesda, MD, November 9-10, 2014

Strategic Considerations for Immuno-Oncology Companies: Role for Vaccines
Nodality, South San Francisco, CA, October 6, 2014

Cancer Immunotherapy: Scientific Breakthrough of 2013
National Institute of Biological Sciences, Beijing, China, September 22, 2014

The Transformation of Oncology: A strategic view of Immunoscore and Immunotherapy
SITC-CAHON-US CACA-CSCO Fourth Joint Symposium, International Track, CSCO, Xiamen, China September, 2014

Cancer Immunotherapy: Scientific Breakthrough of 2013
Harper Cancer Institute, Notre Dame, South Bend, IN, September 5, 2014

Autophagosome-Based Cancer Immunotherapy: DRibbles
Professorship Symposium for Tanja DeGruijl, The Free University, Amsterdam, The Netherlands, June 18, 2014

Transforming the practice of oncology
Keynote address, Annual meeting of the American Academy of Caranial and Maxofacial Surgeons, Portland, Oregon, May 30, 2014

Immunoscore: Immunotherapy at a Tipping Point
Tumor Immunotherapy meets Oncology (TIMO), German Society for Immunology subgroup Meeting, Halle, Germany, May 22, 2014

Exploiting Autophagy to Improve Immunotherapy of Cancer
Tocagen, San Diego, CA, April 4, 2014

Exploiting Autophagy to Improve Immunotherapy of Cancer
Grand Rounds, Karmanos Cancer Institute, Wayne State University, Detroit, MI, April 1, 2014

Exploiting Autophagy to Improve Immunotherapy of Cancer
School of Medicine Seminar Series, Oregon Health & Science University, Portland Oregon, January 27, 2014

Developing an Immunotherapy Strategy for the Effective Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
Poster presented by Tarsem Moudgil, Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, Nov. 7-10, 2013

Novel Strategy to Monitor Apparent Tumor-specific T Cells in Patients with Cancer
Poster presented by Rieneke van de Ven, PhD, Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, Nov. 7-10, 2013

Cytomegalovirus containing TRP2 Antigen Provides Protective Immunity Against the Poorly Immunogenic B16BL6-D5 Melanoma
Poster presented by Michael Neuberger, MD, Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, Nov. 7-10, 2013

The Transformation of Oncology: A strategic View of Immunoscore and Immunotherapy
Invited lecture, November 3, 2013 JNJ lecture Springhouse, PA

A Novel Autophagosome Non-Small Cell Lung Cancer Vaccine Contains Short-lived Proteins, Defective Ribosomal Products, at Least Nine NCI-prioritized Antigens and Ligands for TLR 2, 3, 4, 7 and 9
Oral presentation, Helen J. Ross, MD, World Lung Conference, Sydney, Australia, October 27-30, 2013

The Transformation of Oncology: A Strategic View of Immunoscore, Immunotherapy and the Next Decade
Knight Cancer Institute Retreat, The Resort at the Mountain,Welches, OR, October 17, 2013

UbiVac: A Clinical Stage Immunotherapy Company
Oregon Bioscience Association Annual Meeting, Lake Oswego, OR September 18, 2013

Exploiting Autophagy to Improve Immunotherapy of Cancer
Cancer Center Grand Rounds, Carbone Cancer Center, University of Wisconsin, Madison, WI, June 1, 2013

Tumor Autophagosome-Based Cancer Vaccine Combination Immunotherapy Provides Therapeutic Immunity Against Established Breast Cancer
Tumor Vaccine and Cell Therapy Working Group, Cancer Center, University of Hawaii Medical School, Honolulu, HI, May 2, 2013

Generating and Augmenting Therapeutic Anti-Cancer Immunity
Agonox Maui Conference, Mackenna Resort, Maui, HI, May 1, 2013

Exploiting Autophagy to Improve Immunotherapy of Cancer
Cancer Center Grand Rounds, Moffitt Cancer Center, Tampa, FL, April 11, 2013
Immunoscore and Autophagy: Transforming the Practice of Oncology
Center for Biologics Research (CBER), Food and Drug Administration (FDA), Bethesda, MD, March 7, 2013

Exploiting Autophagy to Improve Immunotherapy of Cancer
University of Pittsburgh Cancer Institute Lecture, Pittsburgh, PA, February 5th, 2013.

Vaccine Strategy Targeting Antigens Expressed by Tumors in their Microenvironment
Melanoma Bridge Meeting, Naples, Italy, December 2nd-4th, 2012

Lung Cancer Immunobiology and Immunoscore: A New Classification System for Cancer?
Mayo Clinic School of Medicine Educational Conference on NSCLC. November 16-17, 2012

Immunoscore and Cancer Vaccines
Roche, Penzberg, Germany, June 28th, 2012

Cancer Vaccines 2012 Nanjing Pharmaceutical Conference, Nanjing, China. June 19th, 2012

Exploiting Autophagy to Improve Immunotherapy of Cancer Tumor Vaccine and Cell Therapy Working Group, Loyola University Medical School, March 30th, 2012

Inflammation and Immune Signatures in Cancer: The Good, the Bad and the Challenge for Immunologists
Knight Cancer Institute Tumor Immunology Retreat, OHSU, Portland, OR December 15, 2011

Exploiting Autophagy to Improve Immunotherapy of Cancer. New Perspectives in the Immunotherapy of Cancer
ESCII/NIBIT meeting, Sienna, Italy. October 19-22, 2011

Challenges for Cancer Immunotherapy in 2011 and Strategies to Unravel Secrets of the Anticancer Immune Response
Fudan University, Shanghai, China. October 14, 2011

Exploiting Autophagy to Improve Immunotherapy of Cancer
The 12th Conference on Tumor Biotherapy, Chinese Society of Tumor Biotherapy, Jinan, October 8-10, 2011

Cancer Immunotherapy 2011: Current Status – Future Hurdles Shandong University, Jinan, China, September 17, 2011

Cancer Immunotherapy 2011: Current Status – Future Hurdles CSCO-SITC-CAHON Joint Symposium. The 14th CSCO Annual Meeting, Xiamen, September 14-16, 2011

Translating and Monitoring Combination Immunotherapy
Canadian Cancer Immunotherapy Consortium (CCIC) Lake Louise, Alberta, Canada, April 8th, 2011.